Advances in endourology have made kidney-sparing treatments a viable treatment option.
“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.
The breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.